Moeder, Christopher B <br/><br/>
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 2007 
 - 5418-25 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2007.12.8033  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--enzymology<br/>Cohort Studies<br/>Female<br/>Humans<br/>Immunohistochemistry--methods<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Protein Array Analysis--methods<br/>Receptor, ErbB-2--analysis<br/>Receptors, Estrogen--analysis<br/>Receptors, Progesterone--analysis